Bone Biologics Co. (NASDAQ:BBLG) Sees Large Decrease in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 48,600 shares, a decrease of 86.2% from the September 30th total of 352,700 shares. Based on an average daily volume of 4,210,000 shares, the short-interest ratio is currently 0.0 days. Approximately 9.3% of the company’s stock are sold short.

Bone Biologics Stock Performance

Shares of BBLG stock traded up $0.01 on Friday, hitting $1.73. The stock had a trading volume of 79,919 shares, compared to its average volume of 1,625,380. The business has a 50 day moving average of $1.66 and a 200 day moving average of $1.62. Bone Biologics has a 12-month low of $0.80 and a 12-month high of $10.56.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($1.39) by $0.72. Equities research analysts forecast that Bone Biologics will post -3.17 EPS for the current fiscal year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.